bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.12.20.629649

Genomic Characterisation of Group B Streptococcus from Argentina: Insights into Prophage Diversity, Virulence Factors and Antibiotic Resistance Genes

Abstract

Group B Streptococcus (GBS) is a commensal bacterium that can cause severe infections in infants and adults with comorbidities. Resistance and reduced susceptibility to antibiotics is continually on the rise, and vaccines remain in-development. Prophages have been reported to contribute to GBS evolution and pathogenicity. However, no studies are available to date on prophage contribution to the epidemiology of GBS isolates from humans in South America. In the context of an Argentinian multicentric study, we had previously phenotypically characterised 365 human GBS isolates from invasive disease, urinary infections and maternal colonisation. These isolates had been whole genome sequenced and their prophage presence bioinformatically determined. In this study, we genomically characterised the isolates and analysed the prophage content in the context of the epidemiological data. The phylogenetic analysis of the 365 genomes with 103 GBS from public databases revealed that Argentinian GBS were related to isolates from around the world. The most prevalent lineages, independently of the isolate source, were CC23/Ia and CC12/Ib. Genes encoding virulence factors involved in immune response evasion, tissue damage and adherence to host tissues and invasion were found in all of the genomes in accordance with previously described lineage distribution. According to the prevalent capsular types and the distribution of specific virulence factors in Argentinian GBS, over 95% coverage would be expected from the vaccines currently under development. Antibiotic resistance determinants (ARDs) to at least one antibiotic class were found in 90% of the genomes, including novel mutations in pbp2x, while more than 15% carried ARDs to 3 or more classes. GBS collected from urinary infections carried a significantly higher proportion of ARDs to multiple antibiotic classes than the rest of the isolates. A total of 454 prophages were found among the 468 genomes analysed, which were classified into 23 prophage types. Prophage presence exhibited variations based on GBS clonal complex and capsular type. A possible association between an increased GBS pathogenicity and the carriage of prophages with integrase type GBSInt8 and/or the presence of genes that encode the Phox Homology domain has been observed. The highest prevalence of prophages per genome was found in lineages CC17/III and CC19/III, while the lowest amount was observed in CC12/Ib. Overall, the highest density of prophages, virulence factors and ARDs determinants was found in CC19 isolates, mostly of capsular type III, independently of the isolates source. This is the first analysis of the human-associated GBS population in South America based on whole genome sequencing data, which will make a significant contribution to future studies on the global GBS population structure. Data summarySupplementary results and figures can be found in Supplementary Material 1. Supplementary tables can be found in Supplementary Material 2. All datasets analysed in this study are detailed in the Supplementary Materials. Metadata about the genomes analysed can be found in the microreact project created for this study: https://microreact.org/project/gbs-pangenomic-analysis. Impact statementIn Latin America studies on the epidemiology of Group B Streptococcus (GBS) are scarce, especially those describing clonal complex and serotype distribution, and the role of prophages in GBS epidemiology has not been studied. This article addresses the first genomic characterisation of the human-isolated GBS population in Latin America based on whole genome sequencing data, with special focus on the analysis of prophage content. We determine the clonal complex and serotype distribution of 365 GBS isolates collected from clinical samples in an Argentinian multicenter study and analyse the presence of prophages and virulence and antibiotic resistance determinants in the context of the epidemiological data. Through these analyses, we were able to determine how GBS population structure in Argentina differs from other parts of the world and to predict the potential coverage of the in-development GBS vaccines. We also found a possible association between the carriage of certain types of prophages and an increased GBS pathogenicity. In the context of increased global efforts to develop new strategies to prevent GBS infections through vaccine development, this study makes a significant contribution to our understanding of the global GBS population structure.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kovacec, V., Di Gregorio, S., Pajon, M., Basit Khan, U., Poklepovich, T., Campos, J., Crestani, C., Bentley, S. D., Jamrozy, D. M., Mollerach, M., Bonofiglio, L.. 2024-12-23. Genomic Characterisation of Group B Streptococcus from Argentina: Insights into Prophage Diversity, Virulence Factors and Antibiotic Resistance Genes. https://doi.org/10.1101/2024.12.20.629649

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

AF3 Inspector: In-Browser 3D Model Visualization and Confidence Analytics for AlphaFold 3

AlphaFold 3 (AF3) has broadened the computational structural biology landscape by predicting all-atom complexes across proteins, nucleic acids, small-molecule ligands, and ions, including chemical modifications. For non-experts, Google provides a fully web-based service to utilize AlphaFold 3. Unfortunately, despite a flexible and rich interface for inputs, the server's outputs are incomplete and complicated for many users, as witnessed hands-on. Not all confidence metrics are displayed, and those that are shown do not present much interactivity; besides, only model number 1 is shown among the 5 produced by the software, and upon download the user finds the models are provided only in CIF format, which is not yet well-known especially among highly practical users. Here, we present the AlphaFold 3 Multi-Model Inspector (AF3 Inspector, https://pdbms.altervista.org/af3viewer/afviewer8.html), an open, client-side, zero-install web application designed to dissect, align, and interactively explore the complete ensemble of structural models produced by AlphaFold 3. Part of the PDB Manipulation Suite (https://pdbms.altervista.org/), the AF3 Inspector operates entirely within web browsers, meaning it is available out of the box in all devices and operating systems. AF3 Inspector delivers 3D visualization in various styles and colors for all models, overlay with backbone alignment if requested, interactive plots for pLDDT profiles, pAE matrices and contact maps, chain-pair interaction heatmaps, automated detection of ligands, ions and post-translational modifications, and rapid mmCIF-to-PDB conversion allowing users to download the more familiar files. The platform addresses critical practical considerations highlighted in recent community benchmarks, such as CASP16, and extends the lightweight, client-side biophysical toolkit paradigm established by the PDB Manipulation Suite (PDBMS).

bioinformatics↗

PanVasc Research for AI assisted evidence analysis in panvascular intervention

Panvascular intervention research requires evidence workflows that preserve source identity, outcome definitions and observation windows. We developed PanVasc Research, an executable research framework, and evaluated a fixed local Qwen3-4B model using two complementary tasks. Fifty ClinicalTrials.gov records from five vascular query strata generated 200 source-fidelity tests with intact evidence or controlled removal of the requested source, primary outcome or timeframe, plus 50 clean controls. A separate 100-statement sample from the official NLI4CT test set assessed clinical-trial entailment and evidence selection against existing expert labels. Generic and checklist prompts used identical evidence and maximum generation budgets; each output was also evaluated with an input-only deterministic contract. Registry exact accuracy was 51/200 (25.5%) with the generic prompt and 77/200 (38.5%) with the checklist; intact-case agreement was 50/50 and 48/50. The rule baseline recovered 200/200 tuples. NLI label accuracy was 48/100 (48.0%) and 50/100 (50.0%), respectively. The source contract retained 35 and 31 incorrect NLI labels in the two arms. Registry references establish fidelity to a registration snapshot, while NLI4CT concerns breast-cancer trials and does not validate vascular expertise. The framework also retains provenance-recorded literature retrieval, structured research planning and local numerical analysis. These experiments support a bounded assessment of source handling and semantic failure, rather than a new foundation model or autonomous scientific discovery. A proposed endpoint representation identifies the additional domain annotation and independent validation required for a panvascular research model.

bioinformatics↗

BiomiX 3.0: A user-friendly platform for democratized multi-omics integration with graph-based learning.

Background Multi-omics integration has emerged as a powerful strategy to decode the molecular complexity of biological systems. However, the diversity of available methods, each designed with distinct assumptions, objectives, and computational requirements, makes method selection, usage and interpretation challenging for nonexpert users. Here we present BiomiX 3.0, an updated version of the BiomiX platform that extends its integration capabilities with four additional methods: Similarity Network Fusion (SNF), NEighborhood-based Multi-Omics clustering (NEMO), Data Integration Analysis for Biomarker discovery using Latent variable approaches for Omics studies (DIABLO), and PRAMIGO (Phenotyping netwoRk Application for Multi-omics InteGratiOn), a novel supervised heterogeneous graph transformer (HGT) introduced in this work. Results We benchmarked all five methods, MOFA, DIABLO, SNF, NEMO, and PRAMIGO, on two independent multiomics datasets derived from a Chronic Lymphocytic Leukemia (CLL) cohort comparing IGHV-mutated and unmutated patients, and a pulmonary tuberculosis (PTB) cohort versus healthy controls. Supervised methods (DIABLO, PRAMIGO) consistently achieved higher condition-specific discrimination as measured by the Adjusted Rand Index (ARI) and the Adjusted Mutual Information (AMI). In contrast, unsupervised methods (SNF, NEMO) revealed alternative patient stratifications driven by independent sources of biological variance while MOFA performed in a semi-supervised way occupies an intermediate position, capturing latent factors that explain both disease-associated and orthogonal sources of variance. Systematic gene-centric analysis of the top-ranked features prioritized by each method was supported by manual biological annotation of shared and method-specific signals. Across cohorts, we annotated 154 shared features (116 genes, 38 metabolites) and 60 method-unique features per cohort, demonstrating that no single integration strategy captures the full landscape of biologically relevant signals. In the CLL cohort, shared features spanned B-cell receptor biology, innate immune signaling, RAS/MAPK activation, and epigenetic regulation, while methodunique features revealed supervised-method-specific insights into vesicle trafficking (DIABLO), immune checkpoints (MOFA), and ncRNA regulation (PRAMIGO). In the PTB cohort, a convergent interferon/innate immune signature dominated shared features across all methods. Still, method-unique analysis uncovered DIABLO-specific acylcarnitine metabolic reprogramming, MOFA-specific restoration of lysosomal trafficking, and PRAMIGO-specific {gamma}{delta} T-cell and immunoglobulin repertoire diversity. Across both cohorts, SNF and NEMO proved useful for detecting biological and technical sources of variation that were orthogonal to the primary condition of interest. Ultimately, PRAMIGO uniquely enables the construction of heterogeneous graphs modeling cross-modal molecular interactions, uncovering epigenetic co-regulation programs in CLL and multi-omics inflammatory modules in PTB that are difficult to identify using conventional integration approaches. Conclusions BiomiX 3.0 provides a graphical user interface (GUI) multi-method integration environment that democratizes access to state-of-the-art multi-omics analysis. By combining both unsupervised and supervised integration strategies within a unified platform and introducing graph-based learning through PRAMIGO, BiomiX 3.0 enables researchers across disciplines with complementary tools to interrogate the biological sources of variation in their data, without requiring bioinformatics expertise.

bioinformatics↗